Last reviewed · How we verify
Xanamem
Xanamem is a Small molecule drug developed by Actinogen Medical. It is currently in Phase 2 development. Also known as: UE2343.
Xanamem is a small molecule intervention being studied for its potential to treat various conditions, including dementia, Alzheimer's disease, and peripheral neuropathy. It works by inhibiting the synthesis of cortisol through the inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xanamem |
|---|---|
| Also known as | UE2343 |
| Sponsor | Actinogen Medical |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (PHASE2, PHASE3)
- A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) (PHASE2)
- A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (PHASE1, PHASE2)
- Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) (PHASE2)
- Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects (PHASE1)
- Xanamem™ in Healthy Elderly Subjects (PHASE1)
- A Phase I Study of Oral UE2343 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xanamem CI brief — competitive landscape report
- Xanamem updates RSS · CI watch RSS
- Actinogen Medical portfolio CI
Frequently asked questions about Xanamem
What is Xanamem?
Who makes Xanamem?
Is Xanamem also known as anything else?
What development phase is Xanamem in?
Related
- Manufacturer: Actinogen Medical — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: UE2343
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing